Literature DB >> 8555072

High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells.

N Juge-Morineau1, M P Mellerin, S Francois, M J Rapp, J L Harousseau, M Amiot, R Bataille.   

Abstract

We have studied the retinoblastoma (RB-1) susceptibility gene status and pRB expression in 22 human myeloma cell lines (HMCL) and in 10 patients with advanced multiple myeloma (MM). Deletions of the RB-1 gene were observed in 81% (17/21) of the informative HMCL, regardless of their paracrine or autocrine interleukin-6 (IL-6) status. Among the deleted HMCL, only one (U266) had a biallelic deletion and lacked pRB expression. Monoallelic deletions had no consequence on the RB-1 gene activation and pRB expression. One patient of 10 presented the same biallclic deletion as U266 and six of 10 had monoallelic deletions. We conclude that monoallelic deletions of the RB-1 gene are frequent in HMCL and MM patients but have no consequence on gene activation and pRB expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8555072     DOI: 10.1111/j.1365-2141.1995.tb05365.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

2.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Authors:  Jan B Egan; Chang-Xin Shi; Waibhav Tembe; Alexis Christoforides; Ahmet Kurdoglu; Shripad Sinari; Sumit Middha; Yan Asmann; Jessica Schmidt; Esteban Braggio; Jonathan J Keats; Rafael Fonseca; P Leif Bergsagel; David W Craig; John D Carpten; A Keith Stewart
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

3.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.

Authors:  Julie O'Neal; Feng Gao; Anjum Hassan; Ryan Monahan; Samantha Barrios; Manfred W Kilimann; Ian Lee; Wee J Chng; Ravi Vij; Michael H Tomasson
Journal:  Exp Hematol       Date:  2009-02       Impact factor: 3.084

Review 4.  Molecular aspects of multiple myeloma.

Authors:  G Pratt
Journal:  Mol Pathol       Date:  2002-10

5.  Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells.

Authors:  Zhiwen He; Julie O'Neal; William C Wilson; Nitin Mahajan; Jun Luo; Yinan Wang; Mack Y Su; Lan Lu; James B Skeath; Deepta Bhattacharya; Michael H Tomasson
Journal:  Exp Hematol       Date:  2015-12-01       Impact factor: 3.084

6.  Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma.

Authors:  Shigeyuki Yokokura; Saki Yurimoto; Akihito Matsuoka; Osamu Imataki; Hiroaki Dobashi; Shuji Bandoh; Takuya Matsunaga
Journal:  BMC Cancer       Date:  2014-11-26       Impact factor: 4.430

7.  Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.

Authors:  Patrick Frost; Yijiang Shi; Bao Hoang; Joseph Gera; Alan Lichtenstein
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

8.  Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.

Authors:  Jessica Wenthe; Sedigheh Naseri; Ann-Charlotte Hellström; Helena Jernberg Wiklund; Emma Eriksson; Angelica Loskog
Journal:  Cancer Gene Ther       Date:  2020-05-01       Impact factor: 5.987

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.